The FDA has approved ruxolitinib (Jakafi, Incyte) for myelofibrosis, a rare bone marrow disease. The agent inhibits the JAK1 and JAK2 enzymes, which play a role in blood regulation and immunological functioning.

 

References

Source: FDA.

For more on the approval, visit www.fda.gov/NewsEvents.